Pro-Dex, Inc. (NASDAQ:PDEX – Get Rating) shares passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $17.31 and traded as low as $15.61. Pro-Dex shares last traded at $15.90, with a volume of 2,677 shares trading hands.
Analyst Upgrades and Downgrades
Separately, StockNews.com began coverage on Pro-Dex in a report on Friday, December 23rd. They set a "buy" rating on the stock.
Get Pro-Dex alerts:Pro-Dex Price Performance
The company has a market capitalization of $56.92 million, a price-to-earnings ratio of 15.29 and a beta of 0.91. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.73 and a quick ratio of 1.39. The business has a fifty day moving average price of $17.38 and a 200 day moving average price of $17.31.
Pro-Dex (NASDAQ:PDEX – Get Rating) last released its earnings results on Thursday, November 3rd. The medical instruments supplier reported $0.29 earnings per share (EPS) for the quarter. The firm had revenue of $11.09 million for the quarter. Pro-Dex had a return on equity of 16.75% and a net margin of 8.97%.Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. State Street Corp grew its holdings in Pro-Dex by 5.8% during the first quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier's stock worth $197,000 after acquiring an additional 650 shares during the period. Dimensional Fund Advisors LP increased its stake in Pro-Dex by 2.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 58,126 shares of the medical instruments supplier's stock worth $1,030,000 after purchasing an additional 1,535 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Pro-Dex by 345.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,687 shares of the medical instruments supplier's stock worth $48,000 after purchasing an additional 2,084 shares in the last quarter. LSV Asset Management increased its stake in Pro-Dex by 13.9% in the 1st quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier's stock worth $588,000 after purchasing an additional 4,346 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Pro-Dex by 59.2% in the 1st quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier's stock worth $345,000 after purchasing an additional 7,762 shares in the last quarter. 13.49% of the stock is owned by institutional investors and hedge funds.
About Pro-Dex
(Get Rating)
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
Further Reading
- Get a free copy of the StockNews.com research report on Pro-Dex (PDEX)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.